187 completed. 187 Phase 2, 58 Phase 1, 25 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 187 | Completed 187 |
| Phase 1 | 58 | Completed 58 |
| Phase 3 | 25 | Completed 25 |
Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
| L9LS in Women of Childbearing Potential in Mali Single dose of 1800 mg L9LS SC, Placebo - Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 279 | 2025-07-22 | 2026-10-30 |
| Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali TB31F, Normal saline - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 167 | 2024-07-12 | 2026-01-22 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2024-01-23 | 2025-11-19 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 60 | 2024-01-23 | 2026-05-07 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
| A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria BNT165c, BNT165d, Placebo - Malaria | Phase 1 / Phase 2 | Completed | BioNTech SE | 163 | 2023-11-13 | 2026-08-28 |
| A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2023-08-18 | 2026-07-20 |
| L9LS MAb in Malian Adults L9LS (VRC-MALMAB0114-00-AB), Placebo - Plasmodium Falciparum Infection, Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 490 | 2023-05-25 | 2025-04-02 |
| Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Completed | Muhimbili University of Health and Allied Sciences | 384 | 2023-05-01 | 2026-09-23 |
| A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum | Phase 1 / Phase 2 | Completed | University of Oxford | 390 | 2023-04-03 | 2026-10-21 |
| Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) M5717 330 mg, M5717 500 mg, M5717 660 mg - Acute Malaria | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 38 | 2023-03-29 | 2025-08-27 |
| Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults R21/Matrix-M vaccination, DHA-PIP, PQ - Malaria,Falciparum | Phase 2 | Completed | University of Oxford | 127 | 2023-01-04 | 2025-07-03 |
| Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Artesunate-amodiaquine combination, Primaquine Phosphate, Artemether-lumefantrine - Malaria,Falciparum | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 100 | 2022-10-17 | 2024-10-01 |
| Anti-malaria MAb in Kenyan Children L9LS, Placebo - Plasmodium Falciparum Infection, Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 912 | 2022-09-14 | 2025-10-16 |
| Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate Argesun 60mg (1 step parenteral artesunate), Artesun 60mg (2-step parenteral artesunate) - Severe Malaria | Phase 2 | Completed | University of Oxford | 200 | 2022-07-18 | 2024-03-15 |
| Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria PfSPZ Vaccine, PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis, Normal Saline - Malaria | Phase 2 | Completed | Sanaria Inc. | 345 | 2022-05-07 | 2026-05-04 |
| PfSPZ Vaccine Trial in Malian Children Sanaria® PfSPZ Vaccine, Normal Saline - Malaria, Malaria,Falciparum | Phase 2 | Completed | Sanaria Inc. | 290 | 2022-04-01 | 2024-02-07 |
| Anti-malaria MAb in Malian Children L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection, L9LS (VRC-MALMAB0114-00-AB) intravenous injection, Placebo - Plasmodium Falciparum Infection, Malaria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 365 | 2022-03-18 | 2025-07-10 |
| To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Cipargamin, IV Artesunate, Coartem - Severe Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 254 | 2022-03-07 | 2026-04-09 |
Showing 20 of 187. Sign in to see all of them.
Malaria, Falciparum (78) · Malaria, Vivax (17) · Parasitic Diseases (4) · Acute malaria (3) · Glucosephosphate Dehydrogenase Deficiency (3) · Malaria, Cerebral (3) · Seizures (3) · Adenoviridae Infections (2) · Coccidiosis (2) · Epilepsy (2) · Fever (2) · Infections (2) · Parasitemia (2) · Anemia (1)
Mosquito-Borne Diseases (187) · Protozoan Infections (186) · Vector Borne Diseases (186) · Infections (185) · Parasitic Diseases (183) · Pathological Conditions, Signs and Symptoms (8) · Hemic and Lymphatic Diseases (7) · Hematologic Diseases (5) · Signs and Symptoms (5) · Anemia (4) · Anemia, Hemolytic (4) · Anemia, Hemolytic, Congenital (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4)
Artemether, Lumefantrine Drug Combination (17) · Primaquine (17) · Amodiaquine (14) · Artesunate (13) · fanasil, pyrimethamine drug combination (13) · Chloroquine (12) · Azithromycin (8) · Saline Solution (8) · RTS malaria vaccine (7) · Rabies Vaccines (7) · tafenoquine (7) · NITD 609 (6) · piperaquine (6) · Matrix-M (5) · Mefloquine (5)
University of Oxford (31) · London School of Hygiene and Tropical Medicine (20) · GlaxoSmithKline (18) · U.S. Army Medical Research and Development Command (16) · Medicines for Malaria Venture (11) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Novartis Pharmaceuticals (10) · Heidelberg University (5) · Pfizer (5) · Sanaria Inc. (5) · Radboud University Medical Center (4) · Malaria Vaccine and Drug Development Center (3) · University of California, San Francisco (3) · University of Rochester (3) · Albert Schweitzer Hospital (2)
Burkina Faso (25) · Mali (25) · Kenya (20) · United Kingdom (19) · United States (19) · Gabon (15) · Thailand (12) · Ghana (10) · Uganda (10) · Mozambique (9) · Tanzania (9) · Colombia (6) · Côte d’Ivoire (6) · Democratic Republic of the Congo (6) · Malawi (6)
Adrian VS Hill, D.Phil, FRCP (4) · Kassoum Kayentao, MD, MPH, PhD (4) · Adrian V S Hill, MD (3) · Brian Greenwood, FRCP, FRS (3) · James McCarthy, Prof (3) · Patrick E Duffy, M.D. (3) · Peter Crompton, MD, MPH (3) · Adrian V Hill, DPhill FRCP (2) · Adrian VS Hill, MA, BM BCh, DPhil, DM (2) · Alassane Dicko (2) · Alassane Dicko, MD (2) · Daniel Chandramohan, MBBS, PhD (2)
PMID 39377226, PMID 28495354, PMID 21443960, PMID 23433102, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 31672143, PMID 35664997, PMID 36875126, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12011004, PMID 12663340, PMID 15069048, PMID 16338450, PMID 16503464, PMID 16904798, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18545693, PMID 18694333, PMID 18752443, PMID 19098989, PMID 19262754, PMID 19365567, PMID 19390585, PMID 19415120, PMID 19517101, PMID 19569964, PMID 19569965, PMID 19649245, PMID 19673614, PMID 19765815, PMID 19789648, PMID 20209126, PMID 20361381, PMID 20557237, PMID 20574538, PMID 20687837, PMID 20735271, PMID 20808923
2015 (2), R01NS074409 (2), 2014 (1), 2016 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1)